ELI LILLY AND COMPANY (NYSE: LLY)

ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Last update: 19 hours ago

1,025.00

-19.67 (-1.88%)

Add to watchlist

Previous Close	1,044.67
Open	1,050.66
Volume	3,535,029
Avg. Volume (3M)	3,403,503
Market Cap	918,868,197,376

Price / Earnings (TTM)	45.45
Price / Earnings (Forward)	31.15
Price / Sales	14.41
Price / Book	39.30

52 Weeks Range	623.78 (-39%) — 1,133.95 (10%)
Earnings Date	30 Apr 2026
TTM Dividend Yield	0.15%

Market Trend

		Short Term	Medium Term
Industry	Drug Manufacturers - General (US)	Bullish	Bullish
	Drug Manufacturers - General (Global)	Bullish	Bullish
Stock	Eli Lilly and Company	Bullish	Bullish

AIStockmoo Score

0.0

Analyst Consensus	1.5
Insider Activity	-1.5
Price Volatility	-0.5
Technical Moving Averages	1.0
Technical Oscillators	-0.5
Average	0.00

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
LLY	919 B	0.15%	45.45	39.30
NVS	302 B	3.27%	21.88	6.47
NVO	218 B	2.24%	13.53	7.15
JNJ	580 B	0.52%	21.81	7.24
ABBV	395 B	0.73%	94.27	50.46
MRK	293 B	0.69%	16.16	5.55

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sector	Healthcare
Industry	Drug Manufacturers - General
Investment Style	Large Growth
% Held by Insiders	0.16%
% Held by Institutions	83.96%

Ownership

Name	Date	Shares Held
Lilly Endowment Inc	31 Dec 2025	92,190,516
Pnc Financial Services Group, Inc.	31 Dec 2025	51,333,220

52 Weeks Range	623.78 (-39%) — 1,133.95 (10%)
Price Target Range	1,161.00 (-99%) — 1,500.00 (-99%)
High	1,500.00 (Citigroup, 46.34%)	Buy
Median	1,274.00 (24.29%)
Low	1,161.00 (Guggenheim, 13.27%)	Buy
Average	1,270.33 (23.94%)
Total	12 Buy
Avg. Price @ Call	1,040.97

Firm	Date	Target Price	Call	Price @ Call
Deutsche Bank	09 Feb 2026	1,285.00 (25.37%)	Buy	1,044.67
Cantor Fitzgerald	05 Feb 2026	1,205.00 (17.56%)	Buy	1,020.84
JP Morgan	05 Feb 2026	1,300.00 (26.83%)	Buy	1,020.84
JP Morgan	18 Nov 2025	1,150.00 (12.20%)	Buy	1,030.05
Morgan Stanley	05 Feb 2026	1,313.00 (28.10%)	Buy	1,020.84
Morgan Stanley	24 Nov 2025	1,290.00 (25.85%)	Buy	1,070.16
Wells Fargo	05 Feb 2026	1,280.00 (24.88%)	Buy	1,020.84
Wells Fargo	10 Dec 2025	1,200.00 (17.07%)	Buy	993.64
Guggenheim	20 Jan 2026	1,161.00 (13.27%)	Buy	1,041.29
UBS	07 Jan 2026	1,250.00 (21.95%)	Buy	1,108.09
B of A Securities	15 Dec 2025	1,268.00 (23.71%)	Buy	1,062.19
BMO Capital	04 Dec 2025	1,200.00 (17.07%)	Buy	1,014.49
Bernstein	24 Nov 2025	1,300.00 (26.83%)	Buy	1,070.16
Truist Securities	19 Nov 2025	1,182.00 (15.32%)	Buy	1,049.60
Citigroup	12 Nov 2025	1,500.00 (46.34%)	Buy	1,017.78
Show more

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
DOZIER ERIC	-	1,037.15	-1,273	-1,320,292
HAKIM ANAT	-	1,037.15	-2,953	-3,062,704
HERNANDEZ EDGARDO	-	1,037.15	-1,591	-1,650,106
JONSSON PATRIK	-	1,037.15	-1,752	-1,817,087
RAU DIOGO	-	1,037.15	-1,674	-1,736,189
RICKS DAVID A	-	1,037.15	-14,297	-14,828,134
SKOVRONSKY DANIEL	-	1,037.15	-5,641	-5,850,563
VAN NAARDEN JACOB	-	1,037.15	-1,909	-1,979,919
YUFFA ILYA	-	1,037.15	-1,512	-1,568,171
Aggregate Net Quantity				-32,602
Aggregate Net Value ($)				-33,813,164
Aggregate Avg. Buy ($)				-
Aggregate Avg. Sell ($)				1,037.15

Name	Holder	Date	Type	Quantity	Price	Value ($)
DOZIER ERIC	Officer	01 Feb 2026	Disposed (-)	1,273	1,037.15	1,320,292
DOZIER ERIC	Officer	01 Feb 2026	Option execute	2,858	-	-
HAKIM ANAT	Officer	01 Feb 2026	Disposed (-)	2,953	1,037.15	3,062,704
HAKIM ANAT	Officer	01 Feb 2026	Option execute	6,700	-	-
HERNANDEZ EDGARDO	Officer	01 Feb 2026	Disposed (-)	1,591	1,037.15	1,650,106
HERNANDEZ EDGARDO	Officer	01 Feb 2026	Option execute	3,572	-	-
JONSSON PATRIK	Officer	01 Feb 2026	Disposed (-)	1,752	1,037.15	1,817,087
JONSSON PATRIK	Officer	01 Feb 2026	Option execute	3,930	-	-
RAU DIOGO	Officer	01 Feb 2026	Disposed (-)	1,674	1,037.15	1,736,189
RAU DIOGO	Officer	01 Feb 2026	Option execute	3,752	-	-
RICKS DAVID A	Officer	01 Feb 2026	Disposed (-)	14,297	1,037.15	14,828,134
RICKS DAVID A	Officer	01 Feb 2026	Option execute	31,932	-	-
VAN NAARDEN JACOB	Officer	01 Feb 2026	Disposed (-)	1,909	1,037.15	1,979,919
VAN NAARDEN JACOB	Officer	01 Feb 2026	Option execute	4,108	-	-
SKOVRONSKY DANIEL	Officer	01 Feb 2026	Disposed (-)	5,641	1,037.15	5,850,563
SKOVRONSKY DANIEL	Officer	01 Feb 2026	Option execute	12,684	-	-
YUFFA ILYA	Officer	01 Feb 2026	Disposed (-)	1,512	1,037.15	1,568,171
YUFFA ILYA	Officer	01 Feb 2026	Option execute	3,394	-	-
Show more

Date	Type	Details
11 Feb 2026	CNBC	Novo Nordisk CEO sees 15 million patient opportunity in Medicare coverage for obesity drugs
11 Feb 2026	CNBC	Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
09 Feb 2026	CNBC	FDA says Novo Nordisk's TV ad for obesity pill includes 'false or misleading' claims
09 Feb 2026	CNBC	Novo Nordisk sues Hims & Hers over copycat versions of Wegovy drugs; Hims stock falls 18%
06 Feb 2026	CNBC	White House launches direct-to-consumer drug site TrumpRx. Here's what to know
04 Feb 2026	CNBC	Eli Lilly's GLP-1 growth is only getting started as Novo Nordisk braces for a decline in 2026
04 Feb 2026	CNBC	Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
04 Feb 2026	Announcement	Lilly reports fourth-quarter 2025 financial results and provides 2026 guidance
03 Feb 2026	CNBC	Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial
30 Jan 2026	Announcement	Lilly selects Pennsylvania as home for its newest injectable medicine and device manufacturing facility
30 Jan 2026	CNBC	Eli Lilly CEO says Medicare coverage of obesity drugs could 'change the game' for upcoming pill launch
30 Jan 2026	CNBC	Eli Lilly plans $3.5 billion manufacturing plant in Pennsylvania to make next-generation obesity injections
23 Jan 2026	CNBC	What obesity drugmakers see next in the market: More pills, easier access and drug combinations
21 Jan 2026	Announcement	Lilly confirms date and conference call for fourth-quarter 2025 financial results announcement
20 Jan 2026	Announcement	Lilly's sofetabart mipitecan receives U.S. FDA's Breakthrough Therapy designation for the treatment of certain patients with platinum-resistant ovarian cancer
16 Jan 2026	CNBC	Novo Nordisk shares rise 8% after Wegovy obesity pill has 'solid' launch
10 Jan 2026	CNBC	2026 is the year of obesity pills. Here's how they could reshape the GLP-1 market
09 Jan 2026	Announcement	Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets
09 Jan 2026	CNBC	Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill
08 Jan 2026	Announcement	Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with active psoriatic arthritis and obesity or overweight
07 Jan 2026	Announcement	Lilly to acquire Ventyx Biosciences to advance oral therapies targeting inflammatory-mediated diseases
05 Jan 2026	CNBC	First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
22 Dec 2025	CNBC	FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
19 Dec 2025	CNBC	Nine of the largest pharma companies ink deals with Trump to lower drug prices
18 Dec 2025	CNBC	Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound
18 Dec 2025	Announcement	Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial
16 Dec 2025	Announcement	Lilly to participate in J.P. Morgan Healthcare Conference
12 Dec 2025	Announcement	Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer
11 Dec 2025	CNBC	Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trial
11 Dec 2025	Announcement	Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial
09 Dec 2025	Announcement	Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisition
09 Dec 2025	CNBC	Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
09 Dec 2025	Announcement	Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
09 Dec 2025	Announcement	Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLL
08 Dec 2025	Announcement	Carolyn Bertozzi returns to Lilly board of directors
08 Dec 2025	Announcement	Lilly declares first-quarter 2026 dividend
07 Dec 2025	Announcement	Lilly's Jaypirca (pirtobrutinib) met its primary endpoint in first-of-its-kind, head-to-head Phase 3 study versus Imbruvica (ibrutinib)
03 Dec 2025	Announcement	U.S. FDA approves expanded indication for Lilly's Jaypirca (pirtobrutinib), the first and only non-covalent (reversible) BTK inhibitor, for adults with relapsed or refractory CLL/SLL previously treated with a covalent BTK inhibitor
01 Dec 2025	CNBC	Eli Lilly cuts cash prices of Zepbound weight loss drug vials on direct-to-consumer site
24 Nov 2025	Announcement	Lilly to present data from two positive Phase 3 studies of Jaypirca (pirtobrutinib) in chronic lymphocytic leukemia at the 2025 American Society of Hematology (ASH) Annual Meeting
24 Nov 2025	Announcement	Lilly to highlight progress across key programs in early and advanced hormone receptor-positive breast cancer at the 2025 San Antonio Breast Cancer Symposium
24 Nov 2025	CNBC	Eli Lilly hits $1 trillion market value, a first in health care, as Novo Nordisk tumbles
19 Nov 2025	Announcement	Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
18 Nov 2025	Announcement	Lilly to participate in Citi's 2025 Global Healthcare Conference
17 Nov 2025	CNBC	Novo Nordisk cuts direct-to-consumer prices for Wegovy, Ozempic to $349 a month
Show more

TTM Dividend Yield	0.15%
5Y Average Dividend Yield	0.78%
Payout Ratio	43.94%

Ex Date	Announcement Date	Payment Date	Details
14 Feb 2025	09 Dec 2024	10 Mar 2025	1.5 Cash
15 Nov 2024	28 Oct 2024	10 Dec 2024	1.3 Cash
15 Aug 2024	24 Jun 2024	10 Sep 2024	1.3 Cash
15 May 2024	06 May 2024	10 Jun 2024	1.3 Cash
14 Feb 2024	08 Dec 2023	08 Mar 2024	1.3 Cash
14 Nov 2023	01 Nov 2023	08 Dec 2023	1.13 Cash
14 Aug 2023	26 Jun 2023	08 Sep 2023	1.13 Cash
12 May 2023	01 May 2023	09 Jun 2023	1.13 Cash
14 Feb 2023	12 Dec 2022	10 Mar 2023	1.13 Cash
14 Nov 2022	17 Oct 2022	09 Dec 2022	0.98 Cash
12 Aug 2022	27 Jun 2022	09 Sep 2022	0.98 Cash
13 May 2022	02 May 2022	10 Jun 2022	0.98 Cash
14 Feb 2022	13 Dec 2021	10 Mar 2022	0.98 Cash
12 Nov 2021	18 Oct 2021	10 Dec 2021	0.85 Cash
12 Aug 2021	29 Jun 2021	10 Sep 2021	0.85 Cash
13 May 2021	03 May 2021	10 Jun 2021	0.85 Cash
11 Feb 2021	14 Dec 2020	10 Mar 2021	0.85 Cash
12 Nov 2020	19 Oct 2020	10 Dec 2020	0.74 Cash
13 Aug 2020	15 Jul 2020	10 Sep 2020	0.74 Cash
14 May 2020	04 May 2020	10 Jun 2020	0.74 Cash
13 Feb 2020	16 Dec 2019	10 Mar 2020	0.74 Cash
14 Nov 2019	22 Oct 2019	10 Dec 2019	0.645 Cash
14 Aug 2019	20 Jun 2019	10 Sep 2019	0.645 Cash
16 May 2019	07 May 2019	10 Jun 2019	0.645 Cash
14 Feb 2019	19 Dec 2018	08 Mar 2019	0.645 Cash
14 Nov 2018	16 Oct 2018	10 Dec 2018	0.5625 Cash
14 Aug 2018	19 Jun 2018	10 Sep 2018	0.5625 Cash
16 May 2018	07 May 2018	08 Jun 2018	0.5625 Cash
14 Feb 2018	11 Dec 2017	09 Mar 2018	0.5625 Cash
14 Nov 2017	16 Oct 2017	08 Dec 2017	0.52 Cash
11 Aug 2017	19 Jun 2017	08 Sep 2017	0.52 Cash
11 May 2017	01 May 2017	09 Jun 2017	0.52 Cash
13 Feb 2017	12 Dec 2016	10 Mar 2017	0.52 Cash
10 Nov 2016	17 Oct 2016	09 Dec 2016	0.51 Cash
11 Aug 2016	20 Jun 2016	09 Sep 2016	0.51 Cash
11 May 2016	02 May 2016	10 Jun 2016	0.51 Cash
10 Feb 2016	08 Dec 2015	10 Mar 2016	0.51 Cash
10 Nov 2015	19 Oct 2015	10 Dec 2015	0.5 Cash
12 Aug 2015	15 Jun 2015	10 Sep 2015	0.5 Cash
14 May 2015	04 May 2015	10 Jun 2015	0.5 Cash
11 Feb 2015	15 Dec 2014	10 Mar 2015	0.5 Cash
12 Nov 2014	20 Oct 2014	10 Dec 2014	0.49 Cash
13 Aug 2014	16 Jun 2014	10 Sep 2014	0.49 Cash
13 May 2014	05 May 2014	10 Jun 2014	0.49 Cash
12 Feb 2014	16 Dec 2013	10 Mar 2014	0.49 Cash
13 Nov 2013	21 Oct 2013	10 Dec 2013	0.49 Cash
13 Aug 2013	18 Jun 2013	10 Sep 2013	0.49 Cash
14 May 2013	03 May 2013	10 Jun 2013	0.49 Cash
13 Feb 2013	17 Dec 2012	08 Mar 2013	0.49 Cash
13 Nov 2012	15 Oct 2012	10 Dec 2012	0.49 Cash
13 Aug 2012	19 Jun 2012	10 Sep 2012	0.49 Cash
13 Feb 2012	12 Dec 2011	09 Mar 2012	0.49 Cash
10 Nov 2011	17 Oct 2011	09 Dec 2011	0.49 Cash
11 Aug 2011	20 Jun 2011	09 Sep 2011	0.49 Cash
11 May 2011	18 Apr 2011	10 Jun 2011	0.49 Cash
11 Feb 2011	13 Dec 2010	10 Mar 2011	0.49 Cash
10 Nov 2010	18 Oct 2010	10 Dec 2010	0.49 Cash
11 Aug 2010	21 Jun 2010	10 Sep 2010	0.49 Cash
12 May 2010	19 Apr 2010	10 Jun 2010	0.49 Cash
10 Feb 2010	14 Dec 2009	10 Mar 2010	0.49 Cash
10 Nov 2009	19 Oct 2009	10 Dec 2009	0.49 Cash
12 Aug 2009	22 Jun 2009	10 Sep 2009	0.49 Cash
13 May 2009	20 Apr 2009	10 Jun 2009	0.49 Cash
11 Feb 2009	15 Dec 2008	10 Mar 2009	0.49 Cash
12 Nov 2008	20 Oct 2008	10 Dec 2008	0.47 Cash
13 Aug 2008	20 Jun 2008	10 Sep 2008	0.47 Cash
13 Feb 2008	17 Dec 2007	10 Mar 2008	0.47 Cash
13 Nov 2007	15 Oct 2007	10 Dec 2007	0.425 Cash
13 Aug 2007	21 Jun 2007	10 Sep 2007	0.425 Cash
11 May 2007	16 Apr 2007	08 Jun 2007	0.425 Cash
13 Feb 2007	18 Dec 2006	09 Mar 2007	0.425 Cash
13 Nov 2006	16 Oct 2006	08 Dec 2006	0.4 Cash
11 Aug 2006	26 Jun 2006	08 Sep 2006	0.4 Cash
11 May 2006	24 Apr 2006	09 Jun 2006	0.4 Cash
13 Feb 2006	19 Dec 2005	10 Mar 2006	0.4 Cash
10 Nov 2005	17 Oct 2005	09 Dec 2005	0.38 Cash
11 Aug 2005	24 Jun 2005	09 Sep 2005	0.38 Cash
11 May 2005	18 Apr 2005	10 Jun 2005	0.38 Cash
11 Feb 2005	20 Dec 2004	10 Mar 2005	0.38 Cash
10 Nov 2004	18 Oct 2004	10 Dec 2004	0.355 Cash
11 Aug 2004	28 Jun 2004	10 Sep 2004	0.355 Cash
12 May 2004	19 Apr 2004	10 Jun 2004	0.355 Cash
11 Feb 2004	15 Dec 2003	10 Mar 2004	0.355 Cash
12 Nov 2003	20 Oct 2003	10 Dec 2003	0.335 Cash
13 Aug 2003	23 Jun 2003	10 Sep 2003	0.335 Cash
13 May 2003	28 Apr 2003	10 Jun 2003	0.335 Cash
12 Feb 2003	16 Dec 2002	10 Mar 2003	0.335 Cash
13 Nov 2002	21 Oct 2002	10 Dec 2002	0.31 Cash
13 Aug 2002	24 Jun 2002	10 Sep 2002	0.31 Cash
13 May 2002	15 Apr 2002	10 Jun 2002	0.31 Cash
13 Feb 2002	17 Dec 2001	08 Mar 2002	0.31 Cash
13 Nov 2001	15 Oct 2001	10 Dec 2001	0.28 Cash
13 Aug 2001	25 Jun 2001	10 Sep 2001	0.28 Cash
11 May 2001	16 Apr 2001	11 Jun 2001	0.28 Cash
13 Feb 2001	18 Dec 2000	09 Mar 2001	0.28 Cash
13 Nov 2000	16 Oct 2000	11 Dec 2000	0.26 Cash
11 Aug 2000	26 Jun 2000	11 Sep 2000	0.26 Cash
11 May 2000	17 Apr 2000	09 Jun 2000	0.26 Cash
11 Feb 2000	20 Dec 1999	10 Mar 2000	0.26 Cash
10 Nov 1999	18 Oct 1999	10 Dec 1999	0.23 Cash
11 Aug 1999	19 Jul 1999	10 Sep 1999	0.23 Cash
12 May 1999	19 Apr 1999	10 Jun 1999	0.23 Cash
10 Feb 1999	21 Dec 1998	10 Mar 1999	0.23 Cash
10 Nov 1998	20 Oct 1998	10 Dec 1998	0.2 Cash
12 Aug 1998	20 Jul 1998	10 Sep 1998	0.2 Cash
13 May 1998	20 Apr 1998	10 Jun 1998	0.2 Cash
11 Feb 1998	15 Dec 1997	10 Mar 1998	0.2 Cash
12 Nov 1997	15 Sep 1997	10 Dec 1997	0.2 Cash
13 Aug 1997	21 Jul 1997	10 Sep 1997	0.36 Cash
13 May 1997	21 Apr 1997	10 Jun 1997	0.36 Cash
12 Feb 1997	16 Dec 1996	10 Mar 1997	0.36 Cash
13 Nov 1996	21 Oct 1996	10 Dec 1996	0.3425 Cash
13 Aug 1996	15 Jul 1996	10 Sep 1996	0.3425 Cash
13 May 1996	15 Apr 1996	10 Jun 1996	0.3425 Cash
13 Feb 1996	18 Dec 1995	11 Mar 1996	0.3425 Cash
13 Nov 1995	17 Oct 1995	11 Dec 1995	0.685 Cash
11 Aug 1995	17 Jul 1995	11 Sep 1995	0.645 Cash
09 May 1995	17 Apr 1995	12 Jun 1995	0.645 Cash
Show more

Annual Dividend Yield

Year	Annual Dividend ($)	Frequency/Year	Yield %
2025	1.50	1	0.14
2024	5.20	4	0.67
2023	4.52	4	0.78
2022	3.92	4	1.07
2021	3.40	4	1.23
2020	2.96	4	1.75
2019	2.58	4	1.96
2018	2.25	4	1.94
2017	2.08	4	2.46
2016	2.04	4	2.77
2015	2.00	4	2.37
2014	1.96	4	2.84
2013	1.96	4	3.84
2012	1.47	3	2.98
2011	1.96	4	4.72
2010	1.96	4	5.59
2009	1.96	4	5.49
2008	1.41	3	3.50
2007	1.70	4	3.18
2006	1.60	4	3.07
2005	1.52	4	2.69
2004	1.42	4	2.50
2003	1.34	4	1.91
2002	1.24	4	1.95
2001	1.12	4	1.43
2000	1.04	4	1.12
1999	0.920	4	1.38
1998	0.800	4	0.90
1997	1.28	4	1.84
1996	1.37	4	3.75
1995	1.98	3	7.02
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	22.67%
Operating Margin (TTM)	42.49%
Diluted EPS (TTM)	12.27
Quarterly Revenue Growth (YOY)	45.20%
Quarterly Earnings Growth (YOY)	23.00%

Total Debt/Equity (MRQ)	243.61%
Current Ratio (MRQ)	1.37
Operating Cash Flow (TTM)	9.32 B
Levered Free Cash Flow (TTM)	-1.82 B

Return on Assets (TTM)	16.45%
Return on Equity (TTM)	77.28%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)